There is some exciting news from the Medicines Patent Pool in that Mylan have signed on to produce a generic glecaprevir/pibrentasvir. https://medicinespatentpool.org/mpp-media-post/the-medicines-patent-pool-and-mylan-sign-agreement-to-scale-up-access-to-first-generic-version-of-hepatitis-c-treatment-glecaprevir-pibrentasvir/ This is really significant for areas of Africa where the subtypes of HCV are very resistant to DAAs, for patient with renal failure and for patients who have failed one or more DAA […]
Tag Archives: mavyret
01
Jan
Jan
A quick note on how to take your DAA medication. Read the package insert and follow the instructions with respect to with (or without) food. For example, for Vosevii Administration with food enhances the oral bioavailability of sofosbuvir, velpatasvir, and voxilaprevir. Relative to fasting conditions, mean sofosbuvir systemic exposure (AUC) increased by 64% to 144%, […]
11
Aug
Aug
By Priti Krishtel Last week, the FDA approved AbbVie’s Mavyret—a new hepatitis C virus (HCV) drug that treats all genotypes of the disease and cures more than 90% of patients within just 8 weeks of treatment. This has been reported as a threat to Gilead Sciences’ dominant position in the market, sparking rumors of a […]